Does the Shingles Vaccine Prevent Dementia? What the Evidence Actually Shows

📋 Simple Summary

The short answer: it might — and the evidence has gotten surprisingly strong in the last couple of years. The shingles vaccine already exists to prevent shingles, a painful nerve rash. But researchers noticed that people who got the shot also seemed to be diagnosed with dementia less often. To find out if that was real, they used clever "natural experiments" — people born just one week apart, where only the younger group was allowed to get the vaccine. The younger group developed dementia about 20% less often. Separate studies in Wales, Australia, and the US, plus a meta-analysis of over 14 million people, all point the same direction. It is not proven by a randomized trial yet, but this is one of the most interesting and consistent findings in dementia prevention in years.

The detailed breakdown continues below for those who want the full science.

Published: September 14, 2026
Evidence Tier: 🥈 Silver (replicated natural experiments + meta-analyses — very strong for observational data, but no randomized trial yet)

Our Take

The evidence suggests the shingles vaccine is associated with a meaningfully lower risk of dementia, and the natural-experiment design makes this much more believable than a typical observational study. But it is still not a randomized trial, so we cannot say it is proven to cause the lower risk. What makes this exciting is how consistent the finding is across different countries, different vaccines, and different study methods — and that the vaccine is already recommended for people 50 and over anyway.

We are researchers, not doctors. Nothing here is medical advice.

What You Need to Know

Shingles is caused by the same virus as chickenpox — the varicella-zoster virus — which hides in your nerves for decades and can re-activate later in life. There is growing interest in whether this and other "neurotropic" herpesviruses (viruses that can infect nerve tissue) play a role in dementia. That idea is what made researchers wonder whether vaccinating against the virus might also protect the brain.

Most of the strongest evidence uses a technique called a natural experiment. In Wales, eligibility for the shingles vaccine depended on your exact date of birth: people born before September 2, 1933, could never get it, while people born on or after that date could. Because there is no meaningful difference between someone born one week before versus one week after that date — except vaccine eligibility — any difference in dementia rates between the two groups is hard to explain away as differences in health, wealth, or lifestyle. That is about as close to a randomized trial as you can get without actually running one.

Key Findings

20% lower dementia risk in a Welsh natural experiment. In a study published in Nature (2025), people eligible for the shingles vaccine had a 20% lower risk of a new dementia diagnosis over 7 years (3.5 fewer cases per 100 people). The result held up when the authors checked it again using death certificates from England and Wales. This used the older live vaccine (Zostavax).
The finding replicated in Australia. A JAMA study (2025) ran the same kind of natural experiment using Australia's shingles vaccination program and found the same thing: about 1.8 fewer dementia diagnoses per 100 people over 7.4 years. Two independent countries, two independent datasets, same result.
The newer Shingrix vaccine shows the same signal. A Nature Medicine study (2024) compared the older live vaccine with the newer recombinant vaccine (Shingrix — the one most people get today). Shingrix was linked to a 17% increase in "diagnosis-free time," or roughly 164 extra days without a dementia diagnosis over 6 years — and it beat two other common vaccines (flu and tetanus) on the same measure.
Large US data: 32% lower risk with two doses. A study of 4.5 million people using US insurance records (Vaccine, 2025) found that people who got both Shingrix doses had a 32% lower risk of dementia than unvaccinated people (a hazard ratio of 0.68 — below 1 means lower risk). One dose gave a smaller, 11% reduction.
Meta-analysis of 14.4 million people: 29% lower risk. A 2025 systematic review pooling cohort studies estimated the shingles vaccine was linked to a 29% lower dementia risk. (Note: an earlier 2024 meta-analysis found the trend but it did not reach statistical significance — a reminder that the early data were mixed before the natural experiments clarified the picture.)

Note: these are risk reductions across large groups. They describe lower odds, not a guarantee for any one person, and they come from observational and quasi-experimental studies, not randomized trials.

❓ Common Questions

Does the shingles vaccine actually prevent dementia?

The best evidence to date suggests it may lower your risk — but this is not proven by a randomized trial yet. Two separate natural experiments in different countries found people who got the shingles vaccine were about 20% less likely to receive a dementia diagnosis over roughly 7 years, and a meta-analysis of 14 million people estimated a 29% lower risk. The consistency across studies is what makes this credible.

Which shingles vaccine was studied?

The early natural experiments used the older live vaccine (Zostavax), which is now discontinued in most countries. The good news is that a 2024 study specifically tested the newer recombinant vaccine (Shingrix) and also found a lower risk of dementia, suggesting the benefit is not limited to the old shot. A large US study of Shingrix specifically found a 32% lower dementia risk with two doses.

How big is the effect?

Across studies, vaccination was linked to roughly a 20–29% lower risk of a dementia diagnosis. In the US study of Shingrix, fully vaccinated people had about a 32% lower risk than unvaccinated people. In absolute terms, the Wales study found about 3.5 fewer dementia diagnoses per 100 people over 7 years — a modest but meaningful difference at a population level.

Is this proof, or just a correlation?

It is strong observational and quasi-experimental evidence, not a randomized trial. The Wales and Australia studies used natural experiments — people born just one week apart were eligible or not — which makes the results much harder to explain away by differences in health, wealth, or behavior. But no randomized controlled trial has confirmed it yet, so it is not considered final proof. That trial is the logical next step and would settle the question.

Should I get the shingles vaccine for this reason?

Talk to your doctor. The shingles vaccine is already recommended for adults 50 and over to prevent shingles itself — a painful rash that can cause lasting nerve pain. The possible added dementia benefit is a bonus, not the primary reason to get it. We are researchers, not doctors, and this is not medical advice.

The Bottom Line

The idea that a shingles shot might also protect your brain is one of the more credible surprises in recent dementia research. The evidence is not a single lucky finding — it has now been replicated in Wales, Australia, and the US, using two different vaccines and multiple methods, and it holds up in a meta-analysis of millions of people. What is still missing is a randomized controlled trial to confirm cause and effect. Until then, the sensible framing is: the vaccine is already recommended for shingles prevention in people 50 and over, and a lower dementia risk may be a welcome side benefit.

Sources

Eyting M, Xie M, Michalik F, et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025. PMID 40175543
Pomirchy M, Bommer C, Pradella F, et al. Herpes Zoster Vaccination and Dementia Occurrence. JAMA. 2025. PMID 40267506
Taquet M, Dercon Q, Todd JA. The recombinant shingles vaccine is associated with lower risk of dementia. Nature Medicine. 2024. PMID 39053634
Tang E, Ray I, Arnold BF, et al. Recombinant zoster vaccine and the risk of dementia. Vaccine. 2025. PMID 39733478
Yin Y, Deng J, Liu J. The association between herpes zoster vaccination and the decreased risk of dementia: A systematic review and meta-analysis of cohort studies. Journal of Alzheimer's Disease. 2025. PMID 40551502
Shah S, Dahal K, Thapa S, et al. Herpes zoster vaccination and the risk of dementia: A systematic review and meta-analysis. Brain and Behavior. 2024. PMID 38687552

Medical Disclaimer: We are researchers, not doctors. Nothing on this page is medical advice, and it is not intended to diagnose, treat, cure, or prevent any disease. Talk to your doctor before making decisions about vaccination or any change to your health routine.